Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Q-Med Launches Modified Sodium Hyaluronate In China

This article was originally published in PharmAsia News

Executive Summary

Swedish-based Q-Med has launched its modified sodium hyaluronate for injection in China. After five years of clinical trial and investigation, the product received approval from China's State FDA at the end of last year. It represents the only approved hyaluronic acid filler for cosmetic and plastic surgery purposes in the country. Q-Med has marketed the subcutaneous filler in more than 70 countries and regions worldwide, including the U.S., Canada, Australia, India, Korea and Singapore, safely treating 10 million cases. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts